Drug Trial Radar · NCT07329972
A Study to Evaluate the Effect of Food and Proton Pump Inhibitor on the Pharmacokinetics of ZN-A-1041 in Healthy Participants
Last checked: Nov 20, 2026Latest source record: May 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Nov 21, 2025
Primary completion
Dec 14, 2025
Study completion Dec 14, 2025
Sponsor
- Lead sponsor
- Genentech, Inc.Roche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Jan 9, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is a phase 1, open-label, randomized, four-period crossover study to evaluate the effect of food and rabeprazole on the ZN-A-1041 tablet formulation in healthy male and female participants.
Conditions
- Healthy Volunteers
Interventions
ZN-A-1041 Formulation 1Drug
Participants will receive a single dose of ZN-A-1041 Formulation 1 on each specified treatment.
ZN-A-1041 Formulation 2Drug
Participants will receive a single dose of ZN-A-1041 Formulation 2 on each specified treatment.
RabeprazoleDrug
Participants will receive an oral administration of rabeprazole twice daily (BID) on days 9, 10, 15, and 16 and a single dose on Days 11 and 17.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Observed Concentration (Cmax)Time frame: Days 1 to 8, 11 to 14, and 17 to 20
- Area Under the Concentration-time Curve (AUC) From Hour 0 to the Last Measurable Concentration (AUC0-t)Time frame: Days 1 to 8, 11 to 14, and 17 to 20
- AUC Extrapolated to Infinity (AUC0-∞)Time frame: Days 1 to 8, 11 to 14, and 17 to 20
- Geometric Mean Ratio and Associated 90% Confidence Interval (CI) of Cmax, AUC0-t, and AUC0-∞Time frame: Days 1 to 8, 11 to 14, and 17 to 20
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Daytona Beach Clinical Rsch Unit
Daytona Beach, Florida
Fortrea Clinical Research Unit - Dallas
Dallas, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.